MoonLake Immunotherapeutics (NASDAQ:MLTX) Announces Quarterly Earnings Results

MoonLake Immunotherapeutics (NASDAQ:MLTX) posted its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12), Briefing.com reports. During the same quarter last year, the company posted ($0.18) EPS.

MoonLake Immunotherapeutics Stock Up 0.4 %

MLTX stock traded up $0.20 during trading on Friday, hitting $50.87. 67,858 shares of the company’s stock traded hands, compared to its average volume of 376,786. The business has a fifty day simple moving average of $49.25 and a two-hundred day simple moving average of $45.32. The firm has a market capitalization of $3.25 billion, a P/E ratio of -55.86 and a beta of 1.28. MoonLake Immunotherapeutics has a 1 year low of $35.53 and a 1 year high of $64.98.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other news, Director Simon Sturge sold 171,000 shares of the business’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $53.72, for a total value of $9,186,120.00. Following the completion of the transaction, the director now directly owns 171,980 shares of the company’s stock, valued at approximately $9,238,765.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 12.02% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a report on Monday, September 23rd. Wedbush reiterated an “outperform” rating and set a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Friday. Finally, Wolfe Research lowered shares of MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a research report on Monday, August 26th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.73.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.